ExpressTec (ExpressTec.bio) is an innovative biopharmaceutical and contract manufacturing entity based in the United States. Founded as an independent entity following a corporate spin-out of the core technology from Ventria Bioscience, ExpressTec manages a proprietary, patented plant-based recombinant protein expression platform.
The company operates a molecular farming or "biopharming" model. Instead of relying on conventional, capital-intensive stainless-steel bioreactors that use mammalian, bacterial, or yeast cell cultures, ExpressTec utilizes agricultural systems—specifically self-pollinating rice plants (Oryza sativa L.)—as biological factories. The platform achieves protein yields significantly higher than typical plant-based systems, offering a highly scalable, chemically defined, and structurally consistent production alternative with a reduced carbon footprint.
Core Technology: The ExpressTec Platform
The foundation of the entity's operations is the ExpressTec expression system, which has been utilized in continuous commercial production for over 25 years. The system leverages genetic bioengineering to encode target therapeutic or industrial proteins directly into the genome of the rice plant.
The Production Process
Cultivation: The engineered rice plants utilize sunlight, soil, water, and air to synthesize the target multi-subunit molecules, monoclonal antibodies, fusion proteins, or enzymes.
Bio-Containment and Expression: The desired proteins naturally collect and concentrate in high densities within the rice-seed endosperm (the tissue inside the seeds).
Harvesting and Purification: Once mature, the rice seeds are harvested using standard agricultural methods. The seeds serve as a naturally stable storage medium for the proteins before downstream processing, milling, extraction, and purification occur under strict quality controls.
Strategic Advantages
Animal-Origin-Free (AOF): Because the expression host is a plant, the resulting proteins have zero risk of carrying human or animal-derived adventitious contaminants, viral pathogens, or prions.
Economic Scalability: Scaling production requires expanding agricultural or greenhouse footprints rather than constructing expensive, specialized cell-culture facilities. This drastically reduces the cost of goods sold (COGS).
Biosafety: Utilizing self-pollinating crops like rice minimizes the risk of gene flow and environmental cross-contamination commonly associated with transgenic open-pollinated plant systems.
Products and Services
ExpressTec splits its operations between providing public-facing contract development and manufacturing organization (CDMO) services and supplying critical materials through its commercial subsidiary, InVitria, Inc.
1. Contract Manufacturing Services (CDMO)
ExpressTec provides direct access to its plant-based platform for external biotechnology and pharmaceutical partners. These services include:
* Custom Expression System Design: Developing custom transgenic rice lines optimized to express complex target molecules, novel vaccines, and industrial enzymes.
* Process Scale-Up: Transitioning protein expression from early-stage greenhouse development into metric-ton commercial production capacity.
2. Commercial Protein Portfolio (Via InVitria)
The proteins manufactured via the ExpressTec system are utilized heavily across advanced therapeutics, vaccine production, and cell and gene therapies. Key product families include:
Recombinant Human Albumin (Exbumin® & Optibumin®): Used extensively as a formulation excipient and stabilizer in injectable biologics, therapeutics, and medical devices. Notably, Exbumin represents the first FDA- and EMA-approved use of plant-derived recombinant albumin in an injectable biologic.
Recombinant Transferrin (Optiferrin®): An animal-free iron supplement optimized for high-performance cell culture media.
Cellastim®: A recombinant human serum albumin optimized specifically to enhance cell growth and viability in cell therapy workflows.
Lacromin® & Lysobac®: Recombinant target proteins and lysozymes used for media optimization and specialized bioprocess applications.
ITSE+A™ Family: Chemically defined, blood-free complete media supplements designed to fully replace animal serum in industrial biomanufacturing.
3. Internal Biotherapeutic Pipeline
ExpressTec leverages its high-yield platform internally to develop a proprietary pipeline of therapeutic candidates. This pipeline targets clinical outcomes in:
* Infectious Diseases: Developing affordable, scalable oral vaccines and protective agents.
* Inflammatory Diseases: Producing recombinant variations of naturally occurring, orally available proteins. The company focuses specifically on duplicating the bio-beneficial components of human colostrum and breastmilk, which are otherwise structurally impractical or unsafe to source from natural donors at a therapeutic scale.
Market Applications
The entity's products and services are deployed across more than 40 countries, supporting hundreds of customer clinical programs in the following sectors:
Cell and Gene Therapy: Supplying chemically defined, blood-free reagents to eliminate lot-to-lot performance variability during T-cell immunotherapy and stem cell expansion.
Vaccine Production: Replacing animal serum components to satisfy modern regulatory expectations for safer, fully defined manufacturing systems.
Human Nutrition and Alternative Proteins: Providing high-purity, sustainable plant-derived proteins designed to improve human nutrition, clean-label manufacturing, and eco-friendly protein synthesis.
Please note: This information is generated by AI. For legal use, verify with company sources.
